Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 16/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.40 |
| ▸ | BRD2 | P25440 | 7/20 | 0.39 |
| ▸ | BRD3 | Q15059 | 7/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23728839 | 1.00 | BRD4 (0.42) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL18249927 | 0.90 | BRD4 (0.53) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL17967444 | 0.90 | BRD4 (0.53) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL13732711 | 0.90 | BRD4 (0.53) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL17967387 | 0.83 | BRD4 (0.49) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL17967411 | 0.83 | BRD4 (0.49) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL17967406 | 0.82 | BRD4 (0.53) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL20885960 | 0.82 | BRD4 (0.53) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL17967407 | 0.82 | BRD4 (0.53) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL23728816 | 0.81 | ERN1 (0.47) | BRD4CYP3A4CYP2C9BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2024-02-15 | — | — | US | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| CN-115768765-A | Methods and compounds for treating genetic diseases | 设计治疗公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-4100404-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021158707-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | DMPK, DTYMK, MYCBP | BRD4 928/4885CYP3A4 4885/4885CYP2C9 4879/4885 |
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, GRN, F13B | BRD4 930/4885CYP3A4 4868/4885CYP2C9 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.